AppleMed Research Group, LLC | Miami, FL
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
Full description
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease). Rimegepant will be further evaluated in this population with as needed use in a 12-week, open-label extension study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
-Target Disease Exclusion:
Primary purpose
Allocation
Interventional model
Masking
600 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Pfizer Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal